SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company that innovates next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that on August 18, 2022, the Compensation Committee of the Board of Directors of Senti Bio granted thirty-five new employees stock options to purchase a total of 421,659 common shares of the Company with an exercise price per share of $1.99. These awards were made under the Company’s 2022 Incentive Action Plan (the Plan).
The awards described above were each granted as an incentive to employees entering the Company’s service pursuant to NASDAQ listing rule 5635(c)(4), and were granted pursuant to the terms of the plan. The Plan was adopted by the Board of Directors of the Company on August 5, 2022.
About Senti Bio
Our mission is to create a new generation of smarter medicines that outsmart complex diseases using new and unprecedented approaches. To do this, we are building a synthetic biology platform that could allow us to program next-generation cell and gene therapies with what we call Gene Circuits. These genetic circuits, which are created from novel and unique combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to their cellular environments. Our goal is to design genetic circuits to improve the intelligence of cell and gene therapies to improve their therapeutic efficacy, accuracy and durability against a wide range of diseases that conventional drugs do not easily treat.
Our synthetic biology platform uses ready-to-use chimeric antigen receptor (CAR-NK) natural killer cells, equipped with Gene Circuit technologies, to target particularly challenging indications in liquid and solid tumor oncology. Our lead development candidate is SENTI-202 for the treatment of acute myeloid leukemia (AML). Other CAR-NK programs include SENTI-301 for the treatment of hepatocellular carcinoma (HCC) and SENTI-401 for the treatment of colorectal cancer (CRC). We have also demonstrated the breadth of our genetic circuits in other modalities and diseases outside of oncology and have partnered with Spark Therapeutics and BlueRock Therapeutics to advance these capabilities.
Contact Senti Bio:
Deb Knobelman, PhD, Chief Financial Officer
investors@sentibio.com
Media:
Kelly Perkins
kelli@redhousecomms.com
Find more information about sentibio.com
Follow us on Linkedin: Senti Biosciences
Follow us on twitter: @SentiBio
Comments are closed.